Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03552471 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

BRCA1 Gene Mutation
BRCA2 Gene Mutation
Folate Receptor Alpha Positive
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Uterine Corpus Carcinoma
Recurrent Uterine Serous Carcinoma
Recurrent Uterine Carcinosarcoma
Platinum Resistant Ovarian Cancer

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Mirvetuximab Soravtansine
OTHER: Pharmacokinetic Study
DRUG: Rucaparib Camsylate

Sponsor

Ohio State University Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]